Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | DDO | Q99489 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.41 |
| ▸ | ASPH | Q12797 | 1/20 | 0.40 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17785057 | 0.98 | HCAR2 (0.46) | HCAR2KDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL26337535 | 0.82 | LMNA (0.42) | LMNAVNN1 | |
| SCHEMBL114553 | 0.79 | ATM (0.51) | KDM4EALDH1A1LMNAMAPK1CYP2C9 | |
| SCHEMBL3545678 | 0.79 | MAPT (0.42) | ALDH1A1LMNAMEN1KMT2AHSD17B10 | |
| SCHEMBL30574354 | 0.79 | ATM (0.51) | KDM4EALDH1A1LMNAMAPK1CYP2C9 | |
| SCHEMBL23167635 | 0.79 | HDAC6 (0.59) | — | |
| SCHEMBL30721127 | 0.79 | HCAR2 (0.50) | HCAR2KDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL898595 | 0.79 | HCAR2 (0.50) | HCAR2KDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL846024 | 0.79 | HCAR2 (0.50) | HCAR2KDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL16215530 | 0.78 | ABL1 (0.35) | ALDH1A1CYP2C9CYP2C19TDP1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| CN-119451678-A | Inhibition of histone deacetylase 6 (HDAC 6) | 艾科尼佐治疗股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119212707-A | Oxadiazole HDAC6 inhibitors and uses thereof | 艾科尼佐治疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240279215-A1 | NAMPT MODULATORS | CYTOKINETICS, INCORPORATED | 2024-08-22 | — | — | US | disclosed |
| EP-3632910-B1 | 3,4-DIHYDROQUINOLINONES AS FXR RECEPTOR AGONISTS | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-11339147-B2 | Lactam compound as FXR receptor agonist | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-05-24 | — | — | US | disclosed |
| CN-109134476-B | Bridged ring piperazine derivative or salt thereof, and preparation method and application thereof | 复旦大学 | 2021-03-19 | — | — | CN | disclosed |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10829486-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACUETICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-2424858-A1 | CXCR3 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-7829586-B2 | Aryl-substituted nitrogen-containing heterocyclic compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| WO-2010126851-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010126851-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273781-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273781-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273781-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | MSD K.K. (JP) | 2009-11-05 | — | — | US | disclosed |
| CN-101277932-A | Aryl-substituted nitrogen-containing heterocyclic compound | BANYU PHARMA CO LTD (JP) | 2008-10-01 | — | — | CN | disclosed |
| EP-1935881-A1 | ARYL-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | OPRL1, NPSR1, NPBWR1 | HCAR2 49/4885KDM4E 4637/4885ALDH1A1 1623/4885 |
| US-20240279215-A1 | NAMPT MODULATORS | NAMPT, SIRT1, NNT | HCAR2 667/4885KDM4E 1782/4885ALDH1A1 758/4885 |
| US-11339147-B2 | Lactam compound as FXR receptor agonist | NR1H4, GPBAR1, SLC10A1 | HCAR2 169/4885KDM4E 4512/4885ALDH1A1 2853/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | HCAR2 279/4885KDM4E 1496/4885ALDH1A1 3140/4885 |
| US-10829486-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, SLC10A1, FXR1 | HCAR2 87/4885KDM4E 4486/4885ALDH1A1 1095/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | HCAR2 4185/4885KDM4E 3399/4885ALDH1A1 2147/4885 |
| US-20100273781-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | HCAR2 139/4885KDM4E 3738/4885ALDH1A1 1720/4885 |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, SLC10A2 | HCAR2 92/4885KDM4E 3975/4885ALDH1A1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.